Victory Capital Management
ORIC icon

Victory Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Victory Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.13M Buy
405,280
+72,520
+22% +$823K ﹤0.01% 1320
2025
Q4 		$2.72M Buy
332,760
+200,540
+152% +$2.31M ﹤0.01% 1505
2025
Q3 		$1.59M Sell
132,220
-410
-0.3% -$4.31K ﹤0.01% 1670
2025
Q2 		$1.35M Sell
132,630
-17,630
-12% -$118K ﹤0.01% 1715
2025
Q1 		$838K Buy
150,260
+52,760
+54% +$461K ﹤0.01% 1879
2024
Q4 		$787K Sell
97,500
-2,250
-2% -$20.6K ﹤0.01% 1902
2024
Q3 		$1.02M Buy
99,750
+3,900
+4% +$38.6K ﹤0.01% 1768
2024
Q2 		$678K Buy
95,850
+7,310
+8% +$65.4K ﹤0.01% 1881
2024
Q1 		$1.22M Sell
88,540
-37,490
-30% -$445K ﹤0.01% 1646
2023
Q4 		$1.16M Buy
126,030
+1,180
+0.9% +$8.53K ﹤0.01% 1646
2023
Q3 		$755K Sell
124,850
-12,180
-9% -$99.8K ﹤0.01% 1804
2023
Q2 		$1.06M Sell
137,030
-21,400
-14% -$122K ﹤0.01% 1645
2023
Q1 		$903K Buy
+158,430
New +$828K ﹤0.01% 1753
2022
Q4 		– Sell
-47,479
Closed -$152K – 2679
2022
Q3 		$152K Sell
47,479
-479
-1% -$1.92K ﹤0.01% 2400
2022
Q2 		$215K Buy
47,958
+39
+0.1% +$156 ﹤0.01% 2328
2022
Q1 		$159K Sell
47,919
-1,757,798
-97% -$15.8M ﹤0.01% 2444
2021
Q4 		$26.5M Buy
1,805,717
+259,394
+17% +$4.04M 0.02% 810
2021
Q3 		$32.3M Buy
1,546,323
+241,963
+19% +$4.9M 0.03% 703
2021
Q2 		$23.1M Buy
1,304,360
+198,986
+18% +$4.36M 0.02% 850
2021
Q1 		$27.1M Buy
1,105,374
+5,081
+0.5% +$161K 0.03% 792
2020
Q4 		$37.2M Buy
1,100,293
+203,159
+23% +$5.83M 0.04% 626
2020
Q3 		$22.4M Buy
897,134
+329,014
+58% +$7.83M 0.03% 742
2020
Q2 		$19.2M Buy
+568,120
New +$18.1M 0.03% 802

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Victory Capital Management's ORIC Position: Q1 2026 in Review

Victory Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 22% in Q1 2026, buying an estimated $823K and bringing the position to 405,280 shares worth $5.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1320.

Victory Capital Management first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $37.2M in Q4 2020. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Victory Capital Management held 405,280 shares of Oric Pharmaceuticals worth $5.13M as of Q1 2026.
  • Victory Capital Management bought 72,520 Oric Pharmaceuticals shares in Q1 2026, an estimated $823K.
  • Oric Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #1320 holding.
  • Victory Capital Management first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Victory Capital Management's Oric Pharmaceuticals position peaked at $37.2M in Q4 2020.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.